Published online 2 June 2008
Haematologica, Vol 93, Issue 8, 1269-1271 doi:10.3324/haematol.12654
Copyright © 2008 by Ferrata Storti Foundation
Pierre-Yves Salaun1,5 ,
Thomas Gastinne2 ,
Eric Frampas3 ,
Caroline Bodet-Milin1,5 ,
Philippe Moreau2,5 ,
Françoise Bodéré-Kraeber1,4,5
The accuracies of MRI and FDG-PET/CT in detecting lesions were concordant in 12/20 patients (60%) and discordant for the remaining 8/20 (40%). Finally, in 10/20 patients (50%), FDG-PET/CT detected plasmacytoma lesions in 18 areas (bone: 8 patients, soft tissue: 2 patients), which were outside the scope. Figure 1 shows a lombar spine plasmacytoma detected by FDG-PET/CT and MRI.
For therapeutic evaluation, 14 FDG-PET/CT, corresponding to an overall 260 regions, were analyzed; 10 FDG-PET/CT (61 regions) compared with MRI. Five patients have been treated by radiotherapy, 6 by chemotherapy and 3 by high-dose chemotherapy and autologous stem cell transplantation. A complete response was observed in the 5 radiated patients and in 2 patients treated by chemotherapy, only a partial response in 4 and none in 3 for the other patients. FDG-PET/CT showed persistent abnormal uptake in 18 sites, all in bone, and disease was confirmed for all these sites. Among the 61 regions compared using both FDG-PET/CT and MRI, the findings were concordant for 9 positive and 45 negative areas and discordant for 7 regions in 3 patients. As a matter of fact, MRI falsely classified 6 positive lesions, each of them being correctly classified by FDG-PET/CT (Figure 1). Se, Sp, PPV and PNV are given in Table 1. 
Haematologica, Vol 93, Issue 8, 1269-1271 doi:10.3324/haematol.12654
Copyright © 2008 by Ferrata Storti Foundation
Monoclonal Gammopathies |
FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma
1 Nuclear Medicine Department
2 Hematology Department
3 Radiology Department, University Hospital Hôtel-Dieu, Nantes
4 Centre de Lutte contre le Cancer Gauducheau, Saint-Herblain
5 Inserm U892, CHU Hôtel-Dieu, Nantes, France
Correspondence: Françoise Bodéré-Kraeber, Service de Médecine Nucléaire, CHU Hôtel-Dieu, 44093 Nantes cedex 01, France. Phone: international +33.240084145. E-mail:francoise.bodere{at}chu-nantes.fr
Plasmacytoma can be confined to bone (solitary bone plasmacytoma) or occur in extramedullary sites (extramedullary plasmacytoma).1–4 Diagnostic criteria are a biopsy-proven lesion of bone or soft tissue with evidence of clonal plasma cells, normal bone marrow with no evidence of clonal plasma cells and absence of end-organ damage.5,6 In a recent study, Zamagni et al. have shown that although MRI of the spine and pelvis still remains the gold standard imaging technique for the detection of bone marrow involvement in multiple myeloma, FDG-PET/CT provides additional and valuable information for the assessment of myeloma bone disease in areas not covered by MRI.7 The purpose of the present study is a prospective comparison of FDG-PET/CT and MRI for the appraisal of the staging and the therapeutic assessment of patients with plasmacytoma.
Twenty-four patients (17 males and 7 females; median age 60 years, age range 35–78) with pathologically documented plasmacytoma were included from June 2003 to June 2007 at the University Hospital of Nantes (France). Patients underwent whole body FDG-PET/CT (also covering skull, upper and lower limbs) and bone marrow MRI at the initial staging and therapy afterwards. The physicians for the therapeutic assessment knew the primary site of the disease. For both ethical and practical reasons, not every suspected involved lesion was evaluated by histology. When histological data were not available, the gold standard, therefore, resulted from an exhaustive analysis of patient data and follow-up.
Twenty-three patients were assessed for pre-therapeutic staging and 14 for therapeutic staging. At baseline staging, 54 tumor sites were confirmed according to the gold standard: 50 in bone areas and 4 in soft tissue areas (head and neck, breast and pelvis).
For the baseline staging, overall 460 regions in 23 patients were analyzed by FDG-PET/CT and 120 regions in 20 patients compared to MRI. FDG-PET/CT showed abnormal uptake in 57 sites (53 in bone areas and 4 in soft tissue areas): 53 foci considered as true-positive (TP) and 4 foci as false-positive (FP). FDG-PET/CT missed 1 lesion (iliac bone) confirmed by biopsy. In the 120 regions explored by MRI, 29 lesions were confirmed as being plasmacytoma, according to the gold standard. MRI detected 32 abnormal images, 27 images considered as TP and 5 as FP. MRI missed 2 lesions. FDG-PET/CT correctly classified the 5 FP and the FN. In those areas, FDG-PET/CT showed 3 foci considered as FP and missed 1 lesion, all correctly classified by MRI. Se, Sp, PPV and PNV were calculated. Results are shown in Table 1.
|
View this table: [in a new window] [Download PPT slide] |
Table 1. FDG PET/CT and magnetic resonance imaging performance for staging and therapeutic assessment.
|
 View larger version (41K): [in a new window] [Download PPT slide] |
Figure 1. Images performed on a 49-year old male with a lombar plasmacytoma. Before treatment, plasmacytoma was detected by FDG PET/CT (A) and MRI (B). After external radiotherapy, FDG PET/CT (C) revealed no abnormal uptake. MRI (D) showed a persistent abnormal spine signal. Follow-up confirmed the absence of recurrence.
|
FDG-PET/CT is a metabolic imaging technique where the scope covers the whole body (from skull to lower limbs). Major advantages of FDG-PET/CT are the ability to perform full body examinations, the potential to detect medullary and extramedullary lesions in one single examination and the possibility of distinguishing new active disease from scar or necrotic tissue. Studies comparing FDG-PET with conventional techniques for plasmacytoma detection have been limited due to the rareness of the disease. To the best of our knowledge, the present study is the first one conceived to assess FDG-PET/CT prospectively in a relatively large series of plasmacytomas for initial staging and therapeutic appraisal. In addition to this, we compared the performance of FDG-PET/CT to that of MRI in most cases. Our results show that FDG-PET/CT has a high performance for initial staging of plasmacytoma. Its performance seems equivalent to that of MRI in spine and pelvic bone. Thus, FDG-PET/CT allows investigation with a larger scope, e.g. soft tissues, skull, ribs and limbs. During initial staging, MRI missed 18 lesions located outside of the scope. Moreover, FDG-PET/CT shows a higher performance than MRI for therapeutic assessment. Indeed, MRI failed to differentiate scars from persistent active lesions, as previously observed for multiple myeloma.7 Our study found a higher performance for plasmacytoma assessment than that published for multiple myeloma.7–10 This is probably due to the generally larger size of usual plasmacytoma lesions. Furthermore, we used a hybrid system of PET integrated with CT, which allows for an exact detection of small and/or slightly active lesions. Such lesions are not easily recognized nor differentiated from soft tissue lesions, when using PET alone. In addition, by means of fused images, where each hypermetabolic lesion was concordant with the morphology of a lesion on the corresponding CT image, we could directly confirm the reliability and specificity of our FDG-PET/CT findings in all patients.
In conclusion, PET-CT proves to be a technique that can be used for the widespread screening of plasmacytoma lesions, both in bone and soft tissues in clinical practice. It can probably also be used to assess therapeutic efficiency.
References
 TOP References |
|---|
- Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999;13:1249-57.[CrossRef][Web of Science][Medline]
- Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993;11:1311-5.
[Abstract/Free Full Text] - Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006;81:693-703.
[Abstract/Free Full Text] - Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002;94:1532-7.[CrossRef][Medline]
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.[CrossRef][Web of Science][Medline]
- Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000;96:2037-44.
[Abstract/Free Full Text] - Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007;92:50-5.
[Abstract/Free Full Text] - Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using FDG-PET. Eur J Haematol Med 2002;29:361-6.
- Durie GM, Waxman AD, D’Agnolo A, Williams CM. Whole body18F-FDG-PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63.
[Abstract/Free Full Text] - Nanni C, Zamagni E, Farsad M, Castelluci P, Tosi P, Cangini D, et al. Role of F18-FDG PET/Ct in the assessment of bone involvement in newly diagnosed multiple myeloma : preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525-31.[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||